10-K/A

SIGNATURES

   Pursuant to the requirements of Section 13 of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized this 22nd day of March, 1996.

                           THE LIPOSOME COMPANY, INC. AND SUBSIDIARIES
                           By:    /s/                          Charles A. Baker
                                     Charles A. Baker

     Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on the 22nd day of March,
1996 on behalf of the Registrant and in the capacities indicated.

/s/  Charles A. Baker     Chairman of the Board, Chief Executive Officer
     Charles A. Baker      Officer and Director (Chief Executive Officer)


/S/  Brian J. Geiger      Vice President Finance and Chief Financial Officer
     Brian J. Geiger


/S/  Dennis A. Rodrigues                                       Controller (Chief
Accounting Officer)
     Dennis A. Rodrigues


/S/  James G. Andress     Director
     James G. Andress


/S/  Morton Collins       Director
     Morton Collins


/S/  Stuart Feiner        Director
     Stuart Feiner


/S/  Robert F. Hendrickson                                       Director
     Robert F. Hendrickson


/S/  Bengt Samuelsson, Dr.                                       Director
     Bengt Samuelsson, Dr.


/S/  Joseph T. Stewart, Jr.                                      Director
     Joseph T. Stewart, Jr.


/S/  Gerald Weissmann, M.D.                                      Director
     Gerald Weissmann, M.D.

/S/  Horst Witzel, Dr.-Ing.                                      Director
     Horst Witzel, Dr.-Ing.

EX-27

 

<ARTICLE> 5
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-29-1996
<PERIOD-END>                               DEC-29-1996
<CASH>                                           1,841
<SECURITIES>                                    28,269
<RECEIVABLES>                                    8,963
<ALLOWANCES>                                   (1,079)
<INVENTORY>                                      9,904
<CURRENT-ASSETS>                                48,780
<PP&E>                                          45,880
<DEPRECIATION>                                (17,588)
<TOTAL-ASSETS>                                  94,555
<CURRENT-LIABILITIES>                           12,139
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           361
<OTHER-SE>                                      74,500
<TOTAL-LIABILITY-AND-EQUITY>                    94,555
<SALES>                                         52,840
<TOTAL-REVENUES>                                59,932
<CGS>                                           16,559
<TOTAL-COSTS>                                   77,810
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 339
<INCOME-PRETAX>                               (17,878)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (17,878)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (17,878)
<EPS-PRIMARY>                                   (0.57)
<EPS-DILUTED>                                        0